Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter, representing 65% annual growth compared to the fourth quarter 2024, and approximately $638.5 million for the full year 2025, representing 66% annual growth compared to the full year 2024. AUVELITY net product sales are expected to be approximately $155.1 million and $507.1 million for the fourth quarter and full year 2025, respectively. SUNOSI net product revenue is expected to be approximately $36.7 million and $124.8 million for the fourth quarter and full year 2025, respectively. SYMBRAVO net product sales are expected to be approximately $4.1 million and $6.6 million for the fourth quarter and full year 2025, respectively, following its commercial launch in June 2025.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Axsome Therapeutics management to meet with B. Riley
- Axsome Therapeutics price target raised to $248 from $163 at UBS
- Axsome Therapeutics price target raised to $225 from $169 at Needham
- Axsome Therapeutics price target raised to $200 from $185 at H.C. Wainwright